Prothena Reversion Antibodies. If this Agreement terminates, except for any termination by Celgene pursuant to Section 10.2 or 10.4 or termination pursuant to Section 10.7, then the provisions of this Section 10.10 (and for the avoidance of doubt, the provisions of this Section 10.10 shall not apply in the case of termination by Celgene pursuant to Section 10.2 or 10.4 or termination pursuant to Section 10.7).
Appears in 4 contracts
Samples: License Agreement (Prothena Corp Public LTD Co), Master Collaboration Agreement, Master Collaboration Agreement (Prothena Corp PLC)
Prothena Reversion Antibodies. If this Agreement terminates, except for any termination by Celgene pursuant to Section 10.2 or 10.4 or termination pursuant to Section 10.710.4, then the provisions of this Section 10.10 10.8 (and for the avoidance of doubt, the provisions of this Section 10.10 10.8 shall not apply in the case of termination by Celgene pursuant to Section 10.2 or 10.4 or termination pursuant to Section 10.710.4).
Appears in 3 contracts
Samples: Global License Agreement (Prothena Corp Public LTD Co), Master Collaboration Agreement, Master Collaboration Agreement (Prothena Corp PLC)
Prothena Reversion Antibodies. If this Agreement terminates, except for any termination by Celgene pursuant to Section 10.2 or 10.4 or termination pursuant to Section 10.710.4, then the provisions of this Section 10.10 10.8 60 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. (and for the avoidance of doubt, the provisions of this Section 10.10 10.8 shall not apply in the case of termination by Celgene pursuant to Section 10.2 or 10.4 or termination pursuant to Section 10.710.4).
Appears in 1 contract
